Study of Ibuzatrelvir for COVID-19 in high-risk patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests if a new medicine called ibuzatrelvir can help people with COVID-19 who have certain health risks avoid severe illness. It is for patients who cannot or choose not to take another COVID-19 pill called Paxlovid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 or older and weigh at least 88 pounds (40 kg).
- You must have tested positive for COVID-19 and have symptoms that started within the last 5 days.
- You must not be able to or willing to take Paxlovid (nirmatrelvir/ritonavir).
- You must have certain risk factors (like being 75 or older, or having conditions like diabetes or heart disease) that make severe COVID-19 more likely.
- You cannot be very sick enough to need hospital care right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This study tests an antiviral pill called molnupiravir to see if it can prevent severe COVID-19 in people who are at high risk and cannot take Paxlovid. If you have mild to moderate COVID-19 symptoms and certain health risks, you may be able to join.
This study tests an experimental oral antiviral, secutrelvir, for people with mild to moderate COVID-19 who are not sick enough to need hospital care. The medicine aims to reduce symptoms and help you recover faster.
Hear when a new COVID-19 SARS-CoV-2 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.